Characteristics of patients undergoing nonmyeloablative and myeloablative HSCT
Patient characteristics . | Nonablative transplantation; n = 44 . | Ablative transplantation; n = 52 . |
|---|---|---|
| Sex, female/male, % | 36/64 | 56/44 |
| Median age, y (range) | 56 (50-65) | 54 (50-64) |
| Disease, n (%) | ||
| CML | 8 (18) | 8 (15) |
| CLL | 5 (11) | 0 |
| MDS | 3 (7) | 23 (44) |
| AL in remission | 6 (14) | 7 (13) |
| AL in relapse | 4 (9) | 7 (13) |
| Lymphoma | 7 (16) | 1 (2) |
| Myeloma | 9 (20) | 0 |
| Myelofibrosis | 0 | 6 (12) |
| RCC | 2 (5) | 0 |
| Prior autologous transplantation (%) | 8 (16) | 0 |
| Donor,* n (%) | ||
| Related | 24 (55) | 30 (58) |
| Unrelated | 20 (45) | 22 (42) |
| Stem cell source, n (%) | ||
| PBSC | 38 (86) | 41 (79) |
| BM | 6 (14) | 10 (19) |
| Both | 0 | 1 (2) |
| Conditioning, n (%) | ||
| Flu + TBI, 2 Gy | 38 (86) | 0 |
| TBI, 2 Gy | 6 (14) | 0 |
| Bu + Cy | 0 | 32 (62) |
| Bu + Flu | 0 | 13 (25) |
| Cy + TBI, more than 10 Gy | 0 | 7 (13) |
| After transplantation immunosuppression, n (%) | ||
| MMF + CSP | 44 (100) | 7 (13) |
| MTX + CSP | 0 | 45 (87) |
| Donor lymphocyte infusions (%) | 1 (2) | 0 |
| Rejections, n (%) | 5 (11) | 0 |
Patient characteristics . | Nonablative transplantation; n = 44 . | Ablative transplantation; n = 52 . |
|---|---|---|
| Sex, female/male, % | 36/64 | 56/44 |
| Median age, y (range) | 56 (50-65) | 54 (50-64) |
| Disease, n (%) | ||
| CML | 8 (18) | 8 (15) |
| CLL | 5 (11) | 0 |
| MDS | 3 (7) | 23 (44) |
| AL in remission | 6 (14) | 7 (13) |
| AL in relapse | 4 (9) | 7 (13) |
| Lymphoma | 7 (16) | 1 (2) |
| Myeloma | 9 (20) | 0 |
| Myelofibrosis | 0 | 6 (12) |
| RCC | 2 (5) | 0 |
| Prior autologous transplantation (%) | 8 (16) | 0 |
| Donor,* n (%) | ||
| Related | 24 (55) | 30 (58) |
| Unrelated | 20 (45) | 22 (42) |
| Stem cell source, n (%) | ||
| PBSC | 38 (86) | 41 (79) |
| BM | 6 (14) | 10 (19) |
| Both | 0 | 1 (2) |
| Conditioning, n (%) | ||
| Flu + TBI, 2 Gy | 38 (86) | 0 |
| TBI, 2 Gy | 6 (14) | 0 |
| Bu + Cy | 0 | 32 (62) |
| Bu + Flu | 0 | 13 (25) |
| Cy + TBI, more than 10 Gy | 0 | 7 (13) |
| After transplantation immunosuppression, n (%) | ||
| MMF + CSP | 44 (100) | 7 (13) |
| MTX + CSP | 0 | 45 (87) |
| Donor lymphocyte infusions (%) | 1 (2) | 0 |
| Rejections, n (%) | 5 (11) | 0 |
CML indicates chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; AL, acute leukemia; RCC, renal cell carcinoma; PBSC, peripheral blood stem cells; BM, bone marrow; Flu, fludarabine; Bu, busulfan; Cy, cyclophosphamide
HLA-matched